Company Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide.
Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell lymphoma and chronic lymphocytic leukemia; FT538 to treat AML and multiple myeloma; FT576 to treat multiple myeloma; FT819 to treat hematologic malignancies and solid tumors; FT536 to treat solid tumors; and FT500 for the treatment of advanced solid tumors.
The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of two off-the-shelf iPSC-derived CAR T-cell product candidates; strategic research collaboration and license agreement with Juno Therapeutics, Inc. to screen for and identify small molecule modulators that enhance the therapeutic properties of genetically-engineered T-cell immunotherapies; and a collaboration and option agreement with Janssen Biotech, Inc.
Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
| Country | United States |
| IPO Date | Oct 1, 2013 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 181 |
| CEO | J. Scott Wolchko |
Contact Details
Address: 12278 Scripps Summit Drive San Diego, California United States | |
| Website | https://www.fatetherapeutics.com |
Stock Details
| Ticker Symbol | FATE |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001434316 |
| CUSIP Number | 31189P102 |
| ISIN Number | US31189P1021 |
| Employer ID | 65-1311552 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| J. Scott Wolchko | Founder, Chief Executive Officer, Chief Financial Officer, President, Principal Financial & Accounting Officer and Director |
| Andrew Henry | Senior Vice President of Clinical Operations |
| Cindy R. Tahl J.D. | Chief Legal & Compliance Officer and Corporate Secretary |
| Dr. Bahram Valamehr M.B.A., Ph.D. | President of Research & Development |
| Dr. Jerome Bressi Ph.D. | Chief Regulatory & Quality Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 29, 2024 | 8-K | Current Report |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 12, 2024 | 10-Q | Quarterly Report |
| Nov 12, 2024 | 8-K | Current Report |
| Nov 08, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Oct 25, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Oct 21, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Aug 30, 2024 | 8-K | Current Report |
| Aug 21, 2024 | 3 | Filing |
| Aug 13, 2024 | 10-Q | Quarterly Report |